Absence of in vivo selection for K13 mutations after artemether–lumefantrine treatment in Uganda by Betty Balikagala et al.
Balikagala et al. Malar J  (2017) 16:23 
DOI 10.1186/s12936-016-1663-1
RESEARCH
Absence of in vivo selection for K13 
mutations after artemether–lumefantrine 
treatment in Uganda
Betty Balikagala1, Toshihiro Mita2*, Mie Ikeda2, Miki Sakurai3, Shouki Yatsushiro4, Nobuyuki Takahashi3, 
Shin‑Ichiro Tachibana2, Mary Auma5, Edward H. Ntege1, Daisuke Ito1, Eizo Takashima1, 
Nirianne Marie Q. Palacpac6, Thomas G. Egwang7, Joseph Okello Onen8^, Masatoshi Kataoka4, Eisaku Kimura6, 
Toshihiro Horii6 and Takafumi Tsuboi1*
Abstract 
Background: Individual drug treatment may select resistant parasites in the human body, a process termed in vivo 
selection. Some single nucleotide polymorphisms in Plasmodium falciparum chloroquine‑resistance transporter 
(pfcrt) and multidrug resistance gene 1 (pfmdr1) genes have been reportedly selected after artemether–lumefantrine 
treatment. However, there is a paucity of data regarding in vivo selection of P. falciparum Kelch propeller domain 
(pfkelch13) polymorphisms, responsible for artemisinin‑resistance in Asia, and six putative background mutations for 
artemisinin resistance; D193Y in ferredoxin, T484I in multiple resistance protein 2, V127M in apicoplast ribosomal protein 
S10, I356T in pfcrt, V1157L in protein phosphatase and C1484F in phosphoinositide‑binding protein.
Methods: Artemether–lumefantrine efficacy study with a follow‑up period of 28 days was conducted in northern 
Uganda in 2014. The above‑mentioned genotypes were comparatively analysed before drug administration and on 
days; 3, 7, and 28 days after treatment.
Results: In 61 individuals with successful follow‑up, artemether–lumefantrine treatment regimen was very effective 
with PCR adjusted efficacy of 95.2%. Among 146 isolates obtained before treatment, wild‑type alleles were observed 
in 98.6% of isolates in pfkelch13 and in all isolates in the six putative background genes except I356T in pfcrt, which 
had 2.4% of isolates as mixed infections. In vivo selection study revealed that all isolates detected in the follow‑up 
period harboured wild type alleles in pfkelch13 and the six background genes.
Conclusion: Mutations in pfkelch13 and the six background genes may not play an important role in the in vivo 
selection after artemether–lumefantrine treatment in Uganda. Different mechanisms might rather be associated with 
the existence of parasites after treatment.
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Background
Since the mid-2000s, artemisinin-based combination 
therapy (ACT) has been deployed as first-line treatment 
for uncomplicated Plasmodium falciparum malaria in 
nearly all malaria endemic countries [1]. The wide-scale 
deployment has been regarded as one of the central 
causes of the recent decline in malaria related morbidity 
and mortality rates [2]. However, since the first report of 
artemisinin-resistant P. falciparum malaria in Western 
Cambodia [3], geographical areas of artemisinin resist-
ance have steadily spread into the Greater Mekong sub-
region [4, 5]. In Africa, although previous clinical trials 
have demonstrated rapid parasite-clearance after ACT 
treatment [6], there is a global concern that artemisinin 
resistance may invade this region following the path 
previously observed in chloroquine and sulfadoxine/
pyrimethamine resistance [7–10].
In 2014, pfkelch13 (PF3D7_1343700) was identified as a 
useful molecular marker for tracking the emergence and 
spread of artemisinin resistant P. falciparum. Pfkelch13 
encodes a 726 amino acid protein with a broad-complex, 
tramtrack, bric-a-brac/poxvirus and zincfinger (BTB/
POZ) domain and a C-terminal 6-blade propeller domain 
[11]. Some mutations in these two domains are associ-
ated with delayed parasite-clearance time following arte-
misinin treatment in Southeast Asia [4, 11]. In addition, 
a recent genome-wide association study has identified 
several single nucleotide polymorphisms (SNPs) that 
are assumed to be background genetic changes for arte-
misinin resistance, these include; D193Y in ferredoxin 
(fd), T484I in multidrug resistance protein 2+ (mdr2), 
V127M in the apicoplast ribosomal protein S10 (arps10), 
I356T in chloroquine-resistance transporter (crt), V1157L 
in protein phosphatase (pph) and C1484F in phosphoi-
nositide-binding protein (pibp) [12]. In Africa, polymor-
phisms in these genes have been occasionally observed, 
but mostly different from those reported in Southeast 
Asia [13, 14]. Therefore, it remains unclear whether the 
existence of these mutations in Africa is a consequence of 
selection induced by anti-malarial usage.
During the period of antimalarial treatment, less sus-
ceptible parasites can be selected in the human body, a 
process termed in  vivo selection. This is because the 
treatment would create drug concentration circum-
stances that are sufficient to kill susceptible, but not less 
susceptible parasites. Previous investigations revealed 
that artemether–lumefantrine (AL) treatment selected 
for parasites harbouring alleles with K76 in pfcrt and 
N86, 184F and D1246 in pfmdr1 [15–17]. However, the 
possibility of similar in vivo selection has not been fully 
investigated in pfkelch13 [18] and the putative back-
ground genes.
In Uganda, AL was adopted as a first line treatment for 
uncomplicated malaria in 2004, but actual implementa-
tion was in 2006. So far, marked clinical efficacy has been 
reported to this regimen; 0–0.5% of cases with residual 
parasites by day 3 [19–28] and 1.0–6.0% of recrudes-
cence [20, 21, 24, 26]. All these values were determined 
microscopically. Molecular assessments using high-sen-
sitive PCR are able to detect sub-microscopic infection 
of parasites during follow-up after anti-malarial treat-
ment, some of which might possess resistant phenotypes 
[29]. In this study, AL clinical efficacy in Gulu, Northern 
Uganda was assessed. Recruited individuals were fol-
lowed up for 28  days after treatment and presence of 
parasites was determined by polymerase chain reaction 
(PCR) to detect sub-microscopic infections. Genotyping 
of pfkelch13 polymorphisms, and putative background 
SNPs for artemisinin resistance in P. falciparum recur-
rent infections was done to evaluate whether AL treat-
ment selected for polymorphisms in a region where it has 
been used for a long time.
Methods
Study site and patients
The study was conducted at the peak of malaria transmis-
sion between May–July and October–November 2014 
at St Mary’s Hospital Lacor in Gulu district, Northern 
Uganda. Malaria transmission in the study region is per-
ennial with an estimated prevalence of >60%, and ento-
mological inoculation rate (EIR) of 100 or more infective 
mosquito bites per person per year [30]. Anopheles funes-
tus is the major mosquito vector and a few infections are 
due to Anopheles gambiae [31]. Malaria control meas-
ures in the region include, indoor residual spraying (IRS), 
long-lasting insecticide-treated nets (LLINs), malaria 
case management with ACT and intermittent preventive 
treatment during pregnancy (IPTp). In particular, IRS has 
been scaled-up since 2009 to cover 10 high-malaria bur-
den districts (Apac, Kole, Gulu, Amuru, Nwoya, Pader, 
Agago, Kitgum, Oyam and Lamwo) in the mid-northern 
region [32]. Symptomatic individuals with P. falcipa-
rum positive results by rapid diagnostic test (RDT) were 
referred to the study physicians. The criteria for recruit-
ment are shown in Additional file 1. Individuals who had 
received anti-malarial treatment within two weeks prior 
to enrollment were excluded from AL efficacy study but 
recruited in the in vivo selection study.
Ethics, consent and permissions
Before enrollment, written informed consent was 
obtained from the participants’ parents or guardians, 
and children aged ≥7 years were assented. The study was 
reviewed and approved by Lacor Hospital Institutional 
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Research and Ethics Committee (LHIREC) (Study pro-
tocol number LHIREC 008/05/2013 and 021/09/13) 
and regulatory approval was obtained from the Uganda 
National Council for Science and Technology (UNCST) 
(HS 1395).
Artemether–lumefantrine treatment and follow‑up 
assessment
For the efficacy study, AL (Coartem®, Novartis 20  mg 
artemether/120  mg lumefantrine tablets) was orally 
administered twice daily for 3 days and follow-up assess-
ments were performed on days 1, 2, 3, 7, and 28 after 
initial drug treatment. Dosage of oral Coartem® was 
adjusted according to the participant’s body weight: 
one (5–14 kg), two (15–24 kg), or three (25–34 kg) tab-
lets. The drug was given as directly observed treatment 
(DOTS) for all patients by study nurses and physicians. 
After each treatment, patients were carefully observed for 
30 min, and the same dose was re-administered if vomit-
ing occurred. Rescue treatment regimen (dihydroarte-
misinin–piperaquine) was administered daily for 3  days 
to any individuals who failed on the initial AL therapy. If 
the recruited patients developed severe malaria during 
follow-up, they were referred to the hospital for paren-
teral artesunate.
At enrollment, venous blood samples (1  mL) were 
obtained from the cubital vein before initial treatment 
except for children <2  years where finger prick sam-
pling was performed. A finger-prick blood sample of 
100  μL was obtained at each follow-up visit. Blood was 
spotted on chromatography filter paper (ET31CHR; 
Whatman Limited, Kent, UK). Haemoglobin (Hb) con-
centration was measured using a portable spectro-
photometer Hemocue Hb 201 (HemoCue, Ängelholm, 
Sweden) on days 0 and 28 or on the day of late clinical 
failure. Anaemic patients with Hb level <10.0 g/dL were 
treated with Ferrous sulphate tablets for 14 days. Plasma 
concentrations of artemether and lumefantrine were not 
measured. Treatment outcomes were classified according 
to WHO guidelines for areas of intense malaria transmis-
sion as: adequate clinical and parasitological response 
(ACPR), early treatment failure (ETF), late clinical failure 
(LCF) and late parasitological failure (LPF) [33].
Microscopic and molecular diagnosis of malaria parasites
Thick and thin blood smears were stained with 2% 
Giemsa for 30 min. The number of parasites was counted 
per 200 white blood cells (WBCs), assuming 8000 WBC/
µL. Parasite density was calculated by averaging inde-
pendent counts made by two microscopists. Discordant 
results (difference in parasite density of >50%) were re-
examined by a third microscopist and, parasite density 
calculated by averaging two closest counts. Slides were 
considered negative if after examination of thick smears, 
no parasite was detected in 100 high power fields. Par-
asite DNA was extracted from a quarter of dried blood 
spot (25 µL) using a QIAamp DNA Kit (Qiagen, Hilden, 
Germany) [34]. In all first visit and follow-up cases, P. 
falciparum infections were assessed by species-specific 
PCR as previously described [35]. Genotyping of mero-
zoite surface protein 1 (msp1), merozoite surface protein 
2 (msp-2) and glutamate rich protein (glurp), was also 
performed to differentiate between recrudescence and 
new infections on day 0 and the day of positive infection 
[36, 37]. Nested PCR products were analysed by electro-
phoresis using 2% agarose for msp-1 and msp-2 and 1.5% 
agarose for glurp. Patient samples were run side by side. 
Gel images were digitised and molecular weights deter-
mined using imagej software [38], an open platform for 
scientific image analysis. Densitometric curves were gen-
erated for each gel lane, and dominant bands in each lane 
were assigned molecular weights. Using reference strains, 
alleles were considered the same if molecular weights 
were within 10 bp for msp 2 and 20 bp for glurp.
Genotyping of drug‑resistant genes
Polymorphisms in pfcrt (K76T) and pfmdr1 (N86Y, 
Y184F, S1034C, N1042D and D1246Y) were determined 
as reported [39, 40]. K13-propeller domain was ampli-
fied by nested PCR, covering almost all the six propel-
ler domain sequences, as described [11]. The sequences 
were aligned using MUSCLE in MEGA software, version 
6.06 [41] with P. falciparum 3D7 full-length sequence of 
K13-propeller domain (PF3D7_1343700) from PlasmoDB 
[42] as reference.
Six background mutations for artemisinin resistance 
(D193Y in fd, T484I in mdr2, V127M in arps10, I356T in 
crt, V1157L in pph and C1484F in pibp) were amplified 
by multiplex PCR using gene specific primers (Additional 
file 2). In brief, 10 μL reaction mixture consisted of 1 μL 
of DNA template, 0.5  μM of 6-primer sets, and Prime-
STAR Max DNA Polymerase (Takara Bio Inc., Otsu, 
Japan). Cycling conditions were: denaturation at 98 °C for 
10 s, followed by 40 cycles of amplification (98 °C for 10 s, 
60  °C for 10  s, and 72  °C for 90  s), with a final elonga-
tion period of 90 s at 72 °C. ExoSAP-IT Kit was used for 
the purification of PCR products. SNP typing was per-
formed on amplified products with 5 μL of reaction mix-
ture consisting of 2.5 μL of Premix Ex Taq (Probe qPCR) 
(Takara Bio Inc.), 0.2 μM of each primer, 0.1 μM of LNA 
probe set, 0.05 μL of ROX Reference Dye II, and 0.5 μL 
of template DNA using the 7500 Real-Time PCR Sys-
tem (Applied Biosystems). Primers and probes for SNP 
assay are also shown (Additional file  2). The probes for 
detecting wild type and mutant SNPs were labeled with 
HEX and 6-FAM (6-carboxyfluorescein) as reporters at 5′ 
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end, respectively. All probes contained Iowa Black® FQ 
(IBFQ) as a dark quencher at 3′ end.
To evaluate performance of the SNP assay system in all 
6 genes, two P. falciparum strains, wild type (3D7) and 
a mutant-type (a strain from Thailand identified during 
preliminary experiments) were used as positive controls. 
Nucleotide sequence data are available in the GenBank™, 
EMBL, and DDBJ databases under the accession num-
bers: LC193525–LC193693.
Statistical analysis
Kaplan–Meier product limit formula was used for the 
estimation of day 28-PCR-adjusted cure rates, which 
was the primary efficacy endpoint. The uncorrected and 
PCR-corrected Kaplan–Meier cumulative treatment 
success rates up to day 28 were calculated for all partici-
pants. Patients were censored when either lost to follow-
up or withdrawn from the study. Either Fisher’s exact test 
or Pearson’s Chi square test (χ2) test were used for com-
parison of categorical variables, and Wilcoxon rank sum 
test was used for the continuous variables. P values <0.05 
were considered statistically significant. R statistical soft-
ware (version 3.2.0; R Foundation for Statistical Comput-
ing) was used for all the statistical analyses.
Results
Studied individuals
A total of 672 patients were screened, out of which 169 
microscopically confirmed P. falciparum mono-infection 
were recruited. Sixty-four of the 169 patients met the 
inclusion criteria for the AL therapeutic efficacy study 
(Fig. 1). The remaining 105 patients were excluded due to: 
anti-malarial-drug usage within two weeks (n = 46), living 
outside the study catchment area (n = 18), severe malaria 
(n = 17) and for other reasons (n = 24). Of the 64 enrolled 
individuals, two were lost to follow-up and one was with-
drawn for taking anti-malarial drugs outside the study 
protocol. This resulted in 61 successfully followed-up 
cases (retention rate = 95.3%). Mean age and parasitaemia 
of the studied individuals were 3.3  years and 11,579  μL 
(parasite density  =  0.26%), respectively (Table  1). Older 
children (≥5  years) tended to have higher parasitaemia 
as compared to the younger children <5 years though not 
statistically significant (p  =  0.31). Other characteristics 
remained comparable between age groups. 
Artemether–lumefantrine treatment outcomes
Excellent early response to AL treatment was observed 
in both age groups (Table  2). Fever was cleared by day 
Fig. 1 Study design of artemether–lumefantrine therapeutic efficacy study
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2 in almost all patients. Only one (1.6%) child (4  years 
and 9  month-old male) showed microscopically resid-
ual parasites on day 3. His parasite density was 1.0% at 
enrollment, gradually decreased on days 1 (0.46%) and 2 
(0.38%), and was still present by day 3 (0.22%, 9960 par-
asites/µL). The 3  days rescue regimen of dihydroarte-
misinin–piperaquine was, therefore, administered, and 
live parasites disappeared. However, pyknotic parasites 
persisted until day 7. Prevalence of parasite-positive 
individuals on day 3 as assessed by PCR was 22.9%, 
whereas it was 1.6% by microscopy. Individuals that 
were parasite positive by PCR (19,026.9 ± 11.3, n = 11) 
on day 3 had significantly (p  =  0.0111) higher median 
parasitaemia at enrollment than the PCR negative group 
(9987.1 ± 10.5, n = 48). This suggests that parasite bio-
mass before treatment may also be associated with treat-
ment success and PCR parasite-positive outcome on day 
3 (Additional file 3).
Table 1 Characteristics of 61 individuals in artemether–lumefantrine efficacy study at enrollment
± values are means and SD
Characteristic <5 years (n = 49) ≥5 years (n = 12)
Gender ratio (male/female) 32/17 5/7
Age (years) 2.7 ± 13.0 5.9 ± 18.8
Temperature (°C) 38.4 ± 1.3 38.5 ± 1.0
Geometric mean parasitaemia (No. of parasites/μL) 10,429.8 ± 10.4 17,746.4 ± 12.4
Haemoglobin (g/dL) 10.0 ± 1.9 10.8 ± 2.5
Gametocytes present (n) 4 (8.2%) 1 (8.3%)
Table 2 Response to artemether–lumefantrine treatment
PCR polymerase chain reaction, WHO World Health Organization
Characteristic Age Total (n = 61)
<5 years (n = 49) ≥5 years (n = 12)
Fever (≥37.5 °C) persistence [n (%)]
 Day 1 11 (22.4) 1 (8.3) 12 (19.7)
 Day 2 3 (6.1) 0 3 (4.9)
 Day 3 0 0 0
Parasite persistence
 Microscopy [n (%)]
  Day 1 40 (81.6) 11 (91.7) 51 (83.6)
  Day 2 13 (26.5) 5 (4.2) 18 (29.5)
  Day 3 1 (2.0) 0 1 (1.6)
 PCR [n (%)]
  Day 1 45 (91.8) 11 (91.7) 56 (91.8)
  Day 2 27 (55.1) 6 (50) 33 (54.1)
  Day 3 11 (22.4) 3 (25) 14 (22.9)
 Gametocyte persistence [n (%)]
  Day 1 4 (8.2) 1 (8.3) 5 (8.2)
  Day 2 3 (6.1) 1 (8.3) 4 (6.6)
  Day 3 3 (6.1) 1 (8.3) 4 (6.6)
 28‑day WHO treatment outcome [n (%)]
  Early treatment failure 0 0 0
  Late clinical failure 2 (4.1) 1 (8.3) 3 (4.9)
  Late parasitological failure 0 0 0
  Adequate clinical and parasitological response 47 (96.0) 11 (91.7) 58 (95.1)
 Cure rate [n (%)]
  PCR unadjusted 47 (96.0) 11 (91.7) 58 (95.2)
  PCR adjusted 47 (96.0) 11 (91.7) 58 (95.2)
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Similar to the excellent early treatment response, 
cumulative-efficacy of AL was high with ACPR ratio of 
95.2% (Table  2). Only three individuals showed LCF on 
day 28 and were later confirmed as reinfection by msp1, 
msp2 and glurp genotyping (Additional file 4). These chil-
dren were all male, aged; 11 months, 3 and 6 years with 
enrollment temperature of 36.8, 39.2 and 39.1 °C and ini-
tial parasitaemia of 1400 μL (0.03%), 99,200 μL (2.2%) and 
96,080 μL (2.1%), respectively. Although all were parasite 
negative by day 2, they had malaria recurrence on day 28 
with parasitaemia of 1840 μL (0.04%), 8460 μL (0.2%) and 
32,120 μL (0.7%), respectively. The children were success-
fully treated with the rescue regimen. Gametocytes were 
observed in five individuals (8.2%) at enrolment, and in 
two cases, persisted until day 7 even after AL treatment.
Drug‑resistance related alleles at enrollment
In addition to 64 patients for the therapeutic efficacy 
study, 105 patients who did not meet inclusion crite-
ria for the therapeutic efficacy study were recruited into 
the molecular epidemiological study for drug resistance. 
In total, 146 P. falciparum confirmed blood samples 
(82/105 with good quality gDNA  +  64 from the thera-
peutic efficacy study) were used for genotyping of drug-
resistance related alleles. Amino acid substitutions in 
Pfkelch13, which have been associated with artemisinin 
resistance in the Greater Mekong Sub region [11] were 
not detected; almost all (98.6%) carried wild-type allele 
and only A578S mutation was observed in two samples 
(1.4%) (Table  3). The six SNPs previously identified as 
background genetic changes for artemisinin resistance 
in Southeast Asia, were also genotyped [12]. All isolates 
harboured wild-type alleles in fd, mdr2, arps10, pph 
and pibp. Mutant alleles were only observed in pfcrt as 
mixed alleles (I356 + 356T) (n = 3). Regarding the other 
polymorphisms in pfcrt, K76T, which is known to be 
the responsible genetic change for chloroquine resist-
ance, was observed in 29.2% of the isolates. In pfmdr1, 
wild-type alleles were nearly fixed at all known polymor-
phic positions other than 184; position 86 (98.0%), 1034 
(98.6%), 1042 (100%) and 1246 (93.7%), respectively. At 
position 184, the prevalence of wild type alleles was high 
(80.4%), but as above, was significantly lower than at the 
other positions (p < 0.0001 by Pearson’s Chi square test).
In vivo selection of drug‑resistance related alleles 
after artemether–lumefantrine treatment
Plasmodium falciparum positivity after AL treatment 
was assessed by PCR in 61 individuals who were treated 
and successfully completed 28  days of follow-up. There 
were 23 PCR positive samples: 14 on day 3, 4 on day 7, 
and 5 on day 28. In pfkelch13 and the six background 
genes for artemisinin resistance (genes encoding for 
ferredoxin, multiple resistance protein 2, apicoplast ribo-
somal protein S10, PfCRT protein, protein phosphatase 
and phosphoinositide-binding protein), all isolates car-
ried wild-type alleles on day 3, 7 and 28 (Fig. 2). Amino 
acid position 76 in pfcrt, wild-type alleles were predomi-
nant at both day 0 (66.3%) and the follow-up period (50% 
on day 3, 66.7% on day 7, and 100% on day 28) (Additional 
file 5). In pfmdr1, wild-type alleles were nearly fixed at all 
polymorphic amino acid positions except for 184 on day 
0. These alleles were completely fixed on the all follow-
up days (day 7 and 28) as well. In contrast, position 184 
remained polymorphic throughout the follow-up period 
without any trend of particular alleles except on day 7 
where mutant alleles predominated (Fig. 3). 
Discussion
The present study revealed that both early and late 
responses to AL were still excellent in this study region 
of northern Uganda even after 8  years of its actual 
implementation as first-line treatment. Only one indi-
vidual (1.6%) showed microscopically detectable para-
sites by day 3. Overall, similar excellent early response 
to AL treatment has been reported in other regions in 
Uganda [19–28]. According to WHO criteria [43] an 
endemic region showing ≥10% cases with detectable 
parasites on day 3 after ACT treatment is regarded as an 
area with suspected artemisinin resistance. The World-
wide Antimalarial Resistance Network (WWARN) pro-
poses a more sensitive benchmark of 5% threshold for 
sub-Saharan Africa because of higher levels of herd 
Table 3 Prevalence of  amino acid substitutions in  the 
putative drug-resistance related genes in  Plasmodium 
falciparum isolates collected before  artemether–lumefan-
trine treatment








Pfkelch13 141 (98.6) 2 (1.4) A578S 0
fd D193Y 127 (100) 0 0
mdr2 T484I 126 (100) 0 0
arps10 V127M 127 (100) 0 0
pph V1157 122 (100) 0 0
pibp C1484F 127 (100) 0 0
Pfcrt K76T 98 (68.1) 42 (29.2) 4 (2.7)
I356T 122 (97.6) 0 3 (2.4)
Pfmdr1 N86Y 141 (98.0) 3 (2.1) 0
Y184F 115 (80.4) 14 (9.8) 14 (9.8)
S1034C 143 (98.6) 2 (1.4) 0
N1042D 145 (100) 0 0
D1246Y 134 (93.7) 9 (6.0) 0
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immunity to malaria in the region [44]. In all cases, how-
ever, the prevalence of day 3 parasite positive individu-
als in the present study was less than the benchmarks for 
artemisinin-resistance.
PCR-confirmed parasite positivity after AL treatment 
was much higher than microscopically confirmed posi-
tivity; 91.8% on day 1, 54.1% on day 2, and 23% on day 
3. These prevalences were similar to two previous studies 
that molecularly assessed parasite positivity in Kenya and 
Tanzania [45, 46]. Beshir et  al. [45] reported that PCR-
confirmed parasite positivity on day 3 would be a good 
predictor for malaria recurrence. In this study, however, 
recurrence frequencies did not differ much between the 
PCR-confirmed parasite positive group (7.7%) and the 
PCR-confirmed parasite negative group (4.2%) on day 3.
Mechanisms of artemisinin resistance have been grad-
ually uncovered albeit the overall picture has not been 
clarified. Enhanced stress response including activa-
tion of unfolded protein response and the PI3K/Pi3P/
AKT pathway is thought to be the main mechanism for 
parasite survival in the presence of artemisinin [47, 48]. 
Pfkelch13 has been elucidated to be involved in these 
processes [49, 50]. In the present analysis, however, nearly 
all parasites harboured wild-type alleles in pfkelch13 at 
enrollment. The only mutation observed in Pfkelch13 
was A578S, which has been widely distributed in Africa 
[13, 14]. Computational modelling reported that A578S 
could potentially disrupt the normal function of the 
Pfkelch13 protein [51]. However, only one study has 
described a close link between A578S and prolonged 
parasite clearance after artemisinin treatment [52] and 
others reported no association [14, 18, 53]. Very recently, 
it has been described that introduction of A578S muta-
tion into Dd2 did not change the in vitro artemisinin sus-
ceptibility determined by ring-stage survival assay [14]. 
This observation partially supports the idea that A578S 
is not an artemisinin resistance related mutation. How-
ever, acquirement of artemisinin resistance would be a 
consequence of multiple genetic changes. As observed in 
this study and others [12], genetic background was differ-
ent between African and Southeast Asian parasites. Since 
Dd2 clone is derived from Indochina, similar transfec-
tion studies using African parasite in addition to further 
in vivo efficacy study and population genetic assessment 
would be required to determine the potential role of 
A578S mutation.
Fig. 2 Allele prevalence in Pfkelch13, fd, mdr2, arps10, crt, pph and pibp among 61 isolates collected before and after artemether–lumefantrine 
treatment. Parasite genotypes were characterized at the time of presentation with malaria (day 0) and for infections detected within 28 days after 
treatment with artemether–lumefantrine (AL). n values represent the number of samples analysed on each day. Wild‑type genotypes are indicated
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In vivo selection analysis revealed that pfkelch13 muta-
tion was not observed in the parasite positive samples 
on day 3, 7 and 28, consistent with the recent observa-
tions [18]. Also, no selection of putative six non-synon-
ymous polymorphisms was observed, suggesting that 
these genetic changes would not be responsible for par-
asite persistence in the present study. In contrast, Pfcrt 
K76 and Pfmdr1 N86/D1246 were observed in all recur-
rent parasites. Prevalence of Pfmdr1 Y184F (33.3%) in 
the recurrent patients was higher than baseline (14%), 
although not statistically significant. These observations 
support the potential selection of Pfcrt K76 and Pfmdr1 
N86/Y184F/D1246 after AL treatment [16, 17]. In  vivo 
selection of these mutations would increase these allele 
prevalences in the parasite population. In fact, the analy-
sis herein revealed much higher allele frequencies than 
previously reported [4]; 68 versus 0% in the Pfcrt K76, 
98.0 versus 9.5% in Pfmdr1 N86 and 93.7 versus 16.9% in 
Pfmdr1 D1246.
One patient showed day 3 parasite positivity in the pre-
sent study. Multiple factors are associated with delayed 
parasite clearance after AL treatment [54]. Quality-
assured artemether–lumefantrine, Coartem®, was used 
and all treatment were administered at the study hospi-
tal using DOTS, suggesting that drug factors were very 
unlikely to have major contribution to the early treat-
ment failure. High initial parasitaemia is considered to be 
the most contributing factor to parasite positivity on day 
3 [44]. However, the baseline parasitaemia of this patient 
was only 0.85%, precluding this possibility. This individ-
ual suffered from sickle cell anaemia with a haemoglobin 
level of 7.8  g/dL. Splenic function to filter parasitized 
red blood cells is impaired in sickle cell anaemia patients 
[55]. Previous meta-analysis also reported that severe 
anaemia was associated with slow parasite clearance and 
indicative of a poor immune response [44, 56]. Addition-
ally, infected parasites carried Pfmdr1 allele combination 
(N86 and D1246) that was reported to be associated with 
sub-microscopic residual parasites on day 3 [57]. Taken 
together, the host factors in addition to parasite innate 
resistant potential might have functioned in the observed 
impaired early response.
Role of the human immunodeficiency virus (HIV)-
infection to malaria treatment efficacy with ACT remains 
to be elusive. Some studies showed a close association 
between HIV infection and lower ACT treatment out-
come [58], but others negated this association [24, 59]. 
In this study, HIV infection was not determined, mainly 
because nearly all patients showed excellent ACT effi-
cacy, and thus, this would not be suitable for the associa-
tion study. However, future studies are expected to clarify 
the potential role of HIV infection to ACT efficacy.
Unlike previous studies with malaria recurrence rates 
of 35–60% after artemether–lumefantrine treatment 
Fig. 3 Allele prevalence in pfcrt K76T and pfmdr1among 61 isolates collected before and after artemether–lumefantrine treatment. Parasite 
genotypes were characterized at the time of presentation with malaria (day 0) and for infections detected within 28 days after treatment with 
artemether–lumefantrine (AL). n values represent the number of samples analysed on each day. Wild‑type, mixed, and mutant genotypes are 
indicated
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in Uganda [20–24, 26], much lower rates (4.9%) were 
observed in the study area. This can be explained by con-
siderably fewer cases of reinfection in this study. More-
over, this is most likely due to considerable decrease in 
malaria prevalence in the study site after the scaled-up 
indoor residual spraying program in the mid-northern 
region [32].
Conclusion
This study demonstrated that AL treatment remains of 
high efficacy for the treatment of P. falciparum malaria 
after 8  years of use in a region of high malaria trans-
mission in Uganda. No clear evidence was obtained for 
the selection of mutant alleles in pfkelch13 and the six-
background genes, all of which have been reported to be 
associated with artemisinin resistance in Southeast Asia. 
Close monitoring of AL efficacy is necessary as we seek 
to understand the influence of anti-malarial treatments 
and parasite persistence, malaria transmission setting 
and different genetic background of parasites and host 
interactions in the mutational process. This work was 
done where very low early treatment failure and recur-
rence as well as scarcity of mutant alleles in pfkelch13 
and the six-background genes were observed; if the cir-
cumstances change, repeated in vivo selection analysis is 
recommended.
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